• AAPL 166.82
  • TSLA 144.61
  • AMZN 179.515
  • MSFT 407.055
  • INTC 34.27
  • EURUSD 1.0712
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. SW /
  3. BSLN.SW

Basilea Pharmaceutica AG (BSLN SW) stock market data APIs

CHF41.5 0.25(0.6%) as of April 23, 2024

Basilea Pharmaceutica AG Financial Data Overview

41.25
41.5
-
41.5
40.65
32-49
493 M
47.7326
12 003 K
158 M
-2
0.577
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'BSLN',
Type: 'Common Stock',
Name: 'Basilea Pharmaceutica AG',
Exchange: 'SW',
CurrencyCode: 'CHF',
CurrencyName: 'Swiss Franc',
CurrencySymbol: 'CHF',
CountryName: 'Switzerland',
CountryISO: 'CH',
ISIN: 'CH0011432447',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Basilea Pharmaceutica AG Fundamental Data is available in our Financial Data APIs

  • Net Revenue 158 M
  • EBITDA 23 185 K
  • Earnings Per Share 0.86
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Basilea Pharmaceutica AG Earnings via APIs

  • Latest Release 2024-02-13
  • EPS/Forecast 0.93

Get Basilea Pharmaceutica AG End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Basilea Pharmaceutica AG latest news via APIs

Cresemba® sales in Latin America trigger first sales milestone payment to Basilea

Basilea Pharmaceutica AG Allschwil, Switzerland, January 19, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of pat...

Basilea announces acquisition of preclinical antibiotics program from Spexis

Basilea Pharmaceutica AG Novel class of antibiotics Bactericidal activity demonstrated in vitro and in vivo against broad range of Gram-negative bacteria, including multidrug-resistant strains Allsc...
Do you have any questions?
support@eodhistoricaldata.com